MENU

Testing for SARS-CoV-2: The Cleveland Clinic Experience

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Medical Director & Co-Chair, Enterprise Laboratory Stewardship Committee, Enterprise Medical Operations, & Director of Microbiology, Virology, Mycology & Parasitology, Clevelaland Clinic
    BIOGRAPHY

Abstract

This presentation will discuss the use of the FDA EUA process to implement SARS-CoV-2 assays to address the COVID-19 pandemic.  The use of a team-based approach, through an Incident Command structure, to optimally address all the operational challenges in validating, implementing and maintaining SARS-CoV-2 testing for the patient population in a large tertiary care referral center.  The presentation we review a comparison of five SARS-CoV-2 assays.   Evaluation of the changes in viral load thoughout the time course of COVID-19 infections will be reviewed, and how this related back to the five test comparison will be discussed.  The importance of the population tested (i.e. high versus low prevalence) will be reviewed, as diagnostic tests are being used as screening tests.  The presentation will review the testing of saliva as an alternate diagnostic specimen, and will explain the benefits and limitations of pool testing of diagnostic specimens.  In conclusion, the presentation will describe how testing is integrated with mitigation strategies necessary to curtail the COVID-19 pandemic.

Learning Objectives:

1. Describe the optimal uses for the various types of SARS-CoV-2 tests (i.e. antigen, antibody, & different nucleic acid amplification assays)

2. Discuss the molecular detection of SARS-CoV-2 during COVID-19 convalescence

3. Discuss the impact of utilizing a test with high (95%) specificity in a diagnostic setting versus screening setting

4. Review the benefits and limitations of testing alternate specimen types (e.g. saliva) and utilizing alternate testing strategies (e.g. pooling) for the detection of SARS-CoV-2


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
MAR 16, 2021 10:00 AM PDT
C.E. CREDITS
MAR 16, 2021 10:00 AM PDT
Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
APR 20, 2021 11:00 AM PDT
C.E. CREDITS
APR 20, 2021 11:00 AM PDT
Date: April 20, 2021 Time: 11:00am (PST), 2:00pm (EST) Identification and confirmation of microbial isolates is crucial in the analysis workflow, providing decision-makers the information...
JUN 29, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
JUN 29, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: June 29, 2021 Time: 7:00am (PDT), 10:00am (EDT) The Unyvero Lower Respiratory Tract Panel demonstrated reliable concordance with culture based methods for organism identification from...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 19, 2021 8:00 AM PDT
C.E. CREDITS
APR 19, 2021 8:00 AM PDT
Date: Apri 19, 2021 Time: 8:00am PDT, 5:00pm CEST Since the inception of modern biological research, BioSafety has evolved into a critical consideration in Good Laboratory Practices (GLP). Wi...
Loading Comments...
Show Resources
Attendees
  • See more